22 April 2020 in Journal of Medicinal Chemistry
1 January 2021 in European Journal of Medicinal Chemistry
13 December 2022 in Journal of Medicinal Chemistry
1 September 2020 in European Journal of Medicinal Chemistry
9 April 2020 in Future Medicinal Chemistry
Proteolysis-targeting chimera (PROTAC) is a new technology to selectively degrade target proteins via ubiquitin-proteasome system. PROTAC molecules (PROTACs) are a class of heterobifunctional molecules, which contain a ligand targeting the protein of interest, a ligand recruiting an E3 ligase and a linker connecting these two ligands. They provide several advantages over traditional inhibitors in potency, selectivity and drug resistance. Thus, many promising PROTACs have been developed in the recent two decades, especially small-molecule PROTACs. In this review, we briefly introduce the mechanism of PROTACs and focus on the progress of small-molecule PROTACs based on different E3 ligases. In addition, we also introduce the opportunities and challenges of small-molecule PROTACs for cancer therapy.
1 May 2021 in European Journal of Medicinal Chemistry